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Introduction: Lung cancer remains the leading cause of tumor-related deaths, despite
advances in the understanding of the disease pathogenesis and in its clinical treatment. It is
crucial to develop novel technologies to discover disease biomarkers and predict individual
therapy response.
Materials and methods: We established 48 patients-derived tumor xenografts (PDTXs)
implanted in the subrenal capsule of immunodeficient mice using thin, precision-cut tumor
tissue slices, derived from five patients affected by non-small cell lung cancer. Twenty-six
tissue slices were immediately processed and implanted at sample recovery [patients-
derived tumor xenografts derived from fresh tissue (dPDTX)], whereas the remaining
sections were cultured on specific organotypic supports at 37°C and 5% CO2 for 24 h
before grafting [patients-derived tumor xenografts derived from cultured tissue (cPDTX)].
At sacrifice, xenografts tissue morphology, proliferation (Ki67), and histotype markers were
analyzed. Oncogenic miRNAs profiles were assessed in PDTXs, human tumors, and serum
from one patient.
Results: Xenografts retained the original cancer features and there were no differences
between dPDTXs and cPDTXs. Squamous cell carcinoma (SCC) xenografts showed a higher
engraftment rate than adenocarcinoma (AC)-derived tumors. At basal time, Ki67 levels were
higher in SCCs than in ACs, and the expression levels of genes associated to a stem cell-like
phenotype were also more expressed in SCC samples.The analysis of oncogenic miRNAs
showed that circulating miR-19b, -21, and -210 levels were correlated with higher Ki67
expression in xenografts.
Conclusion: Our study implemented the PDTX model with thin, precision-cut tumor slices
from small tumors, which could be useful for clinical applications and predictive purposes.
The different engraftment success is likely determined by tumor histotype, high prolifera-
tion index, and the expression of genes essential for cancer stem cells maintenance. Our
PDTXs model could be a valid tool to expand primary tumors for the discovery of new
biomarkers and explore therapeutic options.
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INTRODUCTION
Lung cancer is the principal cause of cancer-related deaths world-
wide. Non-small cell lung cancer (NSCLC) is the major form,
accounting for about 85% of all lung tumors, with three histo-
logical subtypes: adenocarcinoma (AC), squamous cell carcinoma
(SCC), and large cell carcinoma (1).
Abbreviations: AC, adenocarcinoma; DAB, 3,3′-diaminobenzidine; FFPE,
formalin-fixed and paraffin-embedded; H&E, hematoxylin and eosin; NSCLC, non-
small cell lung cancer; NTC24, 24 h culture control; PDTXs, patients-derived tumor
xenografts; cPDTXs, patients-derived tumor xenografts derived from cultured tis-
sues; dPDTXs, patients-derived tumor xenografts derived from fresh tissues; RQ,
relative quantity; SCC, squamous cell carcinoma;T 0, baseline time;V f , final volume;
V i, initial volume.
Although much effort is focused in early disease detection,
NSCLC is often diagnosed at advanced stages, not suitable for sur-
gical resection and characterized by a dismal prognosis. Moreover,
despite several advances in our insights of molecular mecha-
nisms of lung tumorigenesis and therapeutic response, the current
therapies offer only modest survival benefits and drug resistance
commonly arise (2). This failure may at least in part be due to
the pathological and molecular heterogeneity characteristic of this
disease (3).
It is crucial to develop novel technologies in order to discover
new biomarkers and predict individual therapy response. In vivo
models able to mimic patients’ malignancies are useful tools to
target this need.
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The patients-derived tumor xenografts (PDTXs), also called
mice avatar, are in vivo models which are based on the graft
of human tumor fragments in immunocompromised mice (4).
Xenografts retain the histopathological and genetic features of the
original cancers making the PDTX a valid method to expand pri-
mary tumors, predict cancer response to therapy, and to determine
new therapeutic markers (5). However, different factors including
tumor histotype, grade, and the site of the transplant can influence
the success of the graft. Moreover, tissue fragments must be rapidly
processed and the original material is often insufficient (6, 7).
Recently, we perfected an ex vivo platform suitable to culture
thin, precise-cut tissue slices from a variety of pathological and
normal tissues in a biological context that strictly resemble the
original microenvironment (8, 9).
In order to overcome PDTXs limits, we combined PDTX
method with our ex vivo tissue culture platform. We established
48 subrenal capsule grafts using thin, precise-cut, 300µm-thick
tumor tissue slices derived from five NSCLC patients. Tissue slices
were immediately processed and implanted at the sample recov-
ery [patients-derived tumor xenografts derived from fresh tissue
(dPDTX)] or cultured for 24 h and subsequently grafted with the




Primary human lung tumors were obtained from five patients who
underwent surgery for therapeutic purposes at Fondazione IRCCS
Ca’ Granda, Policlinico Hospital (Milan, Italy). The patients’ clini-
copathologic features are shown in Table 1. Patients did not receive
neo-adjuvant chemotherapy and/or radiotherapy before surgery.
Blood samples were collected from two patients. Informed consent
was obtained from all patients and the study was approved by the
Institutional Review Board of the Fondazione IRCCS Ca’ Granda.
TISSUE SLICES PREPARATION
Lung cancer tissue slices (300µm-thick) were obtained through
serial cutting of the individual samples using a vibratome VT1200
(Leica Microsystems, Wetzlar, Germany), as previously described
(8). Tissue processing was performed within 20 min after sur-
gical resection. For all specimens, the first tissue slice was
collected (baseline sample, T 0), formalin-fixed and paraffin-
embedded (FFPE) for morphological and immunohistochemical
analyses.
ORGANOTYPIC TISSUE CULTURES
Tissue slices were cultured as already described (8). Briefly, NSCLC
sections were cultured on specific organotypic inserts (Millipore,
Darmstadt, Germany) for 24 h at 37°C in a humidified incubator
with 5% CO2. Culturing media consisted of Ham F-12 media sup-
plemented with 20% inactivated FBS (Life Technologies, Carlsbad,
CA, USA), 100 U/mL penicillin (Life Technologies), 100µg/mL
streptomycin (Life Technologies), 2.5µg/mL amphotericin B, and
100µg/mL of kanamycin (Sigma Aldrich, St. Louis, MO, USA).
For each tumor, a tissue slice was harvested after 24 h of culture,
FFPE, and used as control [24 h culture control (NTC24)] for
morphological and immunohistochemical analyses.
Table 1 | Clinicopathological characteristics of NSCLC studied (n=5).
Sample Gender Age Histotype G T N
SCC1 M 45 Squamous cell carcinoma G2 pT2a N1
AC2 F 83 Adenocarcinoma G3 pT1b N2
AC3 F 75 Adenocarcinoma G3 pT1a N0
SCC4 M 53 Squamous cell carcinoma G3 pT2a N0
AC5 M 74 Adenocarcinoma G2 pT2a N0
Tumor stage according to TNM staging systems and tumor grade are indicated.
XENOGRAFTS ESTABLISHMENT
Three hundred micrometer-thick tissue slices were cut into mul-
tiple 3 mm× 3 mm pieces and submerged in sterile PBS sup-
plemented with antibiotics (10% Pen Strep; Life Technologies).
Forty-eight tissue fragments were grafted under the renal capsule
of 6–8 weeks old CD1 athymic mice (Charles River Laboratories,
Calco, Italy; one graft/kidney) within 1 h, as previously described
(10). Twenty-six tissue slices were immediately processed and
implanted at sample recovery (dPDTX) whereas the others were
cultured for 24 h and subsequently grafted (cPDTX). At 1.5, 3,
and 6 months from the graft, mice were sacrificed and xenografts
were collected. Individual tumor volumes were calculated as
V = (LWS)/2 where L and W are longer and shorter axis, respec-
tively, and S is the xenograft thickness. L and W were measured
using a caliper, whereas S was determined by DMD108 microscope
(Leica Microsystems). The variation of tumor size was expressed
as the final volume (V f) and initial volume (V i= 1.35 mm3) ratio.
Tumors were considered engrafted when they retained viable can-
cer tissue (engraftment rate). Lungs, liver, the contralateral normal
kidney, and spleen were harvested and FFPE for evaluation of
metastatic foci. For 42 mice, blood sample was collected at sacrifice
by cardiac puncture.
Animal care and experiments were performed in accordance
with the Principles of Laboratory Animal Care (NIH Publication
No. 86-23, revised 1985) and approved by the Local Commit-
tee for Experimental Animal Research. Mice were anesthetized
by i.p. injection with fresh 2,2,2-tribromoethanol (Avertin, Sigma
Aldrich) and sterile practices were followed during the surgical
procedure. SCC4 mice were sacrificed after heavy sedation with
a dose of 500 mg/kg of avertin by i.p (Sigma Aldrich) at 1.5 and
3 months because they showed pain symptoms with a progressive
degeneration of their physical condition starting from the first
month after grafting.
MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
In order to assess tissue morphology, hematoxylin and eosin
(H&E) staining was performed. Tumor tissues immunoreactiv-
ity for Ki67, CK5/6, P63, TTF1, NAP-A, CD31, vimentin (antigen
retrieval by EDTA at 95°C for 36 min), or SOX2 (antigen retrieval
by citrate buffer at 95°C for 44 min) was analyzed. All primary anti-
bodies except SOX2 (Cell Signaling, Danvers, MA, USA) were from
Ventana Medical Systems (Roche Group, Tucson, AZ, USA). Indi-
vidual primary antibodies were detected using specific secondary
antibodies and visualized by 3,3′-diaminobenzidine (DAB) and
counterstained with hematoxylin. Negative controls were prepared
in the absence of primary antibody and included in each reaction.
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Three investigators (Silvano Bosari, Alessandro Del Gobbo, and
Stefano Ferrero) independently examined and scored the slides.
When differences arose, the cases were reviewed until a consen-
sus was reached. For quantification of proliferative activity, a Ki67
score was determined as the percentage of positive tumor cells.
Immunoreactivity for CK5/6, P63, TTF1, NAP-A was quantified
as the percentage of positive tumor cells. SOX2 levels were deter-
mined using a two-score system for percentage of positive cells
and intensity of staining. The staining intensity was expressed in
a scale of 0 (absent staining) to 3 (strong staining). Representative
images were acquired using a DMD108 system (Leica Microsys-
tems) and contrast/brightness was adjusted using identical settings
with Photoshop (Adobe Systems Inc., San Jose, CA, USA).
RNA PURIFICATION AND REVERSE TRANSCRIPTION
Total RNA was purified from FFPE samples of NSCLC tissues and
corresponding non-neoplastic lung parenchyma using the Master-
Pure RNA purification kit (Epicentre, Madison, WI, USA) follow-
ing the manufacturer’s instructions. RNA from serological spec-
imens of human or murine origin was isolated using miRNeasy
serum/plasma kit (Qiagen, Limburg, Netherlands) according to
the supplier’s protocol. Before RNA purification, an exogenous
small RNA (cel-miR-39; Qiagen) was added to each serum samples
for normalization of extraction procedures. RNA was quanti-
fied spectrophotometrically. For gene expression quantification,
300 ng of total RNA were reverse-transcribed using the high-
capacity cDNA reverse transcription kit (Life Technologies) in a
V f of 20µL.
Conversely, for miRNAs profiling, 33 ng of total RNA were
reverse-transcribed using the TaqMan MicroRNA reverse tran-
scription kit with the Megaplex RT Primers Human Pool A
v.2.1 and then preamplified using the TaqMan PreAmp Master
Mix with the Megaplex PreAmp Primers Human Pool A v.2.1,
according to the manufacturer’ specifications (Life Technologies).
For serum miRNAs analysis, cel-miR-39-specific RT primers and
probe (192 and 32 nM, respectively; from Life Technologies) were
added to the reverse transcription and pre-amplification reactions,
respectively.
REAL TIME RT-PCR (qPCR)
Expression levels of genes and miRNAs were analyzed in dupli-
cate using gene-specific primers and TaqMan probes (Table S1 in
Supplementary Material) and the ABI Prism 7900HT sequence
detection system (Life Technologies). Targets raw data (C t values)
were converted into relative quantities using GeNorm software
and then median-normalized and log2-transformed for statistical
analysis (11). β-2 microglobulin (β2M ) and actinβ (ACTβ) were
used as reference genes for target relative quantification. Mamma-
ryU6 and RNU48, or miR-16 and miR-39 were used as reference
genes for relative quantification of tissue or serum target miRNAs,
respectively. The serum of a 3 and 6 months old mouse without
grafts was used as control in order to normalize serum miRNAs
contents with respect to the animals’ age.
STATISTICAL ANALYSIS
The association between Ki67 levels and PDTXs volume increase
was evaluated by Fisher’s exact test. Data were analyzed using
Prism 4.0 (GraphPad Inc., La Jolla, CA, USA). The expression pro-
files of genes and miRNAs in tissue and serum samples were ana-
lyzed using the DNA-Chip Analyser Software (http://www.dchip.
org) as previously described (12). The variance of miRNAs levels
according to xenografts features, such as volume variation, Ki67
score, duration of grafts, and engraftment success was analyzed
by ANOVA test provided within DNA-Chip Analyser Software.
Differences among samples group were analyzed using the Mann–
WhitneyU test (GraphPad Inc.). Volume variation was considered
high (H) when it was >1 and low (L) when it was ≤1. Ki67 lev-
els were considered high (H) when Ki67 immunoreactivity was
>50% and low (L) when it was ≤50%.




Tumor tissue slices of 300µm thickness were obtained from five
patients affected by NSCLC and used to establish 48 first gen-
eration PDTXs, as outlined in Figure 1. At mice sacrifice (1.5,
3, and 6 months after implantation) xenografts, and specifically
SCC-derived PDTXs displayed evident vascularization (asterisks
in Figure 2A). Morphologic analysis of the primary tumors and
the corresponding xenografts revealed that 29 PDTXs closely
resembled the original cancer (H&E staining; Figure 2B). Con-
versely, the remaining 19 xenografts (39.6%) did not retain
FIGURE 1 | Schematic overview of the experimental design.
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FIGURE 2 | PDTX establishment from vibratome-generated NSCLC
tissue sections. First generation PDTXs were established by implanting
300µm-thick NSCLC tissue slices under mice renal capsule.
(A) Representative macroscopic images of three xenografts at harvesting.
Asterisks indicate xenograft superficial vascularization. (B)Tissue morphology
was determined by H&E and representative images of SCC and AC-PDTXs
are shown. AC-PDTXs exhibited the epithelial compartment only at
1.5 months from the graft. The absence of epithelial cancer cells is evident in
AC-PTDTXs harvested at 3 and 6 months. Black arrow heads indicate stromal
cells. Original magnification is 200×. (C) Schematic representation of PDTXs
engraftment rates. (D,E) Quantification of AC (average of AC2, 3, and 5
samples); (D) SCC1 and SCC4-PDTXs. (E) Volume variation compared to initial
tumor volume (V i) at different time points, respectively. For all experiments,
bars represent mean±SEM.
tumor epithelial compartment resulting in a total engraftment
rate of 60.4% (Figure 2C). In particular, PDTXs derived from
SCC tumors (SCC-PDTXs) showed a higher engraftment rate
than xenografts derived from AC tissues (AC-PDTXs, 95.5 vs.
30.8%). AC-PDTXs retained the tumor epithelial component
only at 1.5 months from the graft (Figure 2B), whereas these
xenografts showed only stromal tissue at 3 and 6 months from
the graft as evidenced by microscopic (H&E staining, Figure 2B)
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and immunohistochemistry (vimentin staining, Figure S1 in
Supplementary Material) analyses.
In regards to the ex vivo cultures for 24 h of NSCLC tissue
slices before grafting, no significant difference in engrafting rate
or retention of epithelial compartment was evidenced in cPDTXs
compared to dPDTXs. Moreover, dPDTXs and cPDTXs exhibited
comparable engraftment rates in SCC (91.7 vs. 100%) or AC (28.6
vs. 33.3%) derived grafts, as shown in Figure 2C.
When we analyzed the xenografts volume variation, we
observed that tumors growth was higher in SCC-PDTXs (volume
variation range: 0.5–363.8) than AC-PDTXs (volume variation
range: 0.17–1.36). Indeed, most of the xenografts derived from
AC samples (24/26, 92.3%) did not increase their volume com-
pared to their initial mass (Figure 2D). In contrast, 19 (86.3%)
xenografts derived from SCC slices increased their mass compared
to their original volume (Figure 2E). Interestingly, SCC-PDTXs
showed heterogeneity in tumor growth rate, and two patterns
characterized by a slow or fast volume increase were identified.
Morphological examination of PDTXs revealed that SCC4-derived
xenografts presented large necrotic areas, whereas necrosis was
absent in SCC1-PDTXs (not shown). Nevertheless, the difference
in cell death did not prevent SCC4-PDTXs to have a higher and
faster growth rate than SCC1-derived xenografts (Figure 2E).
Finally, we analyzed liver, lung, contralateral kidney, and spleen
for presence of distant metastases at animals’ sacrifice. No metasta-
tic foci were detected by macroscopic or microscopic (H&E)
analyses (Figure S2 in Supplementary Material).
RETENTION BY XENOGRAFTS OF THE ORIGINAL CANCER BIOLOGICAL
FEATURES
In order to compare primary tumors and corresponding PDTXs,
xenografts were investigated for the presence of distinctive his-
tological markers of their original cancer. Therefore, P63 and
CK5/6 immunoreactivity was analyzed in xenografts derived from
SCC samples (Figures 3A–C), whereas NAP-A and TTF1 stains
were investigated in AC-PDTXs (Figures 3D–F). As previously
described (8), the levels of distinctive histological markers were
preserved after 24 h of ex vivo culture (Figure S3 in Supplementary
Material).
In xenografts cell type-specific markers, levels were preserved
at all harvesting points compared to the original cancer and irre-
spective of the NSCLC histotype. Moreover, despite a marginal
reduction in CK5/6 observed in SCC-cPDTXs at 1.5 months, no
significant difference of these proteins levels was observed between
dPDTXs and cPDTXs at later harvesting schedules, i.e., 3 or
6 months. TTF1 immunoreactivity was preserved in AC-PDTXs
at 1.5 months, whereas NAP-A levels showed a slight reduction in
PDTXs tissues that was not statistically significant.
PROLIFERATION INDEX
Ki67 levels were analyzed in xenografts, in NTC24 cultures,
and in the corresponding human cancer. No loss of tissue pro-
liferative potential was evidenced between baseline (T 0) and
NTC24 samples. Regarding xenografts, SCC-PDTXs maintained
high Ki67 levels compared to their primitive cancer and NTC24
at all time points (Figures 4A,B). No significant difference in
Ki67 immunoreactivity was shown between dPDTX and cPDTX
derived from SCC samples. Conversely, AC-PDTXs exhibited
lower Ki67 levels than their original cancer (Figures 4A,C). Nev-
ertheless, no significant difference was highlighted at 1.5 months
after the graft between dPDTX and cPDTX derived from AC
samples.
We therefore looked for differences in proliferative potential in
human NSCLC samples that could account for the distinct behav-
ior of SCC-PDTXs respect to AC-PDTXs. SCC tissues showed
higher proliferative index than AC samples at baseline (Figure S4
in Supplementary Material) or after 24 h of ex vivo culture (Ki67
score range: 55–80 or 5–20%, respectively; Figure 4D). In partic-
ular, SCC4 tumor showed higher Ki67 levels than SCC1 (80 vs.
55% of Ki67-positive cells; Figure S4 in Supplementary Material).
Moreover, PDTXs generated from tissues exhibiting an elevated
proliferative index (Ki67-positive cells >50%) significantly dis-
played a higher growth in vivo (volume variation >1, p< 0.0001;
Figure 4E).
EXPRESSION ANALYSIS OF GENES RELATED TO A STEM CELL
PHENOTYPE
To gain insights on the different SCC and AC engraftment rates,
the expression levels of four stem cell-related genes, namely
ALDH1A1, c-MYC, NANOG, and SOX2 (Table S1 in Supplemen-
tary Material), were analyzed in T 0 and in NTC24 samples. The
gene expression analysis identified SOX2 and ALDH1A1 as the
most deregulated transcripts in SCC compared to AC samples
at baseline and after 24 h of ex vivo culture, with an increased
expression of more than 100- or 16-folds in SCC tumors respect
to AC. Moreover, SOX2 and ALDH1A1 expression levels were sig-
nificantly higher in SCC tissues compared to AC and correlated
with the engraftment success (p< 0.001 by ANOVA; Figure 5A).
c-MYC was also more expressed in SCC than in AC tissues (7- and
36.4-fold differences for T 0 and NTC24 samples, respectively),
whereas NANOG showed a mild overexpression in AC-NSCLC
tissues at baseline (0.5-fold difference) that was not confirmed in
NTC24 samples (1.6-fold difference). Finally, c-MYC andNANOG
expression levels were not correlated to the engraftment rates.
SOX2 protein levels were investigated by immunohistochem-
istry in control tissues (T 0 and NTC24 samples), and in their cor-
responding xenografts. Confirming gene expression data, SOX2
protein levels were more elevated in SCC than AC samples
(Figure 5B). SOX2 expression was maintained after 24 h of ex
vivo culture and in xenografts derived from SCC tissue slices
(Figure 5C). In contrast, SOX2 was poorly expressed by AC sam-
ples, either inT 0,NTC24 samples or in their corresponding PDTXs
at all harvesting points (Figures 5B,C). No significant differences
were demonstrated in SOX2 staining between dPDTX and cPDTX
derived from either SCC or AC lung cancers (Figure 5C).
TISSUE AND SERUM miRNAs EXPRESSION ANALYSIS
Lastly, to investigate whether our model supported the discov-
ery of new biomarkers, we analyzed in SCC tissues or serum the
expression of seven miRNAs (miR-19a, miR-19b, miR-20a, miR-
21, miR-31, miR-150, and miR-210) known to be involved in lung
cancer (13, 14).
Variation of miRNAs expression levels in SCC-PDTXs tis-
sues (Figure 6A) or serum (Figure 6B) was investigated relative
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FIGURE 3 | Morphological and histological analysis of PDTXs. NSCLC
histotypes-specific markers and morphology were analyzed in xenografts.
(A–C) SCC-derived PDTXs were analyzed for P63 and CK5/6
immunoreactivity at the indicated harvesting schedules and compared to
the corresponding human tissue. Representative images of P63 and CK5/6
staining SCC cases are shown in (A), and are quantified in (B,C). Original
magnification 200×. (D–F) Immunoreactivity of AC-PDTXs and
corresponding human tissues for NAP-A and TTF1 markers was analyzed,
and a representative AC case is shown. (D) Quantification of NAP-A (E) and
TTF1 (F) proteins levels in T 0, NTC24 samples, and relative xenografts at
1.5 months after the graft. Original magnification 200×. For all experiments,
bars represent mean±SEM.
to xenografts proliferation, volume variation, and type and
duration of the graft. MiR-19a levels in PDTX tissues were
inversely correlated with Ki67 immunoreactivity (p= 0.03 by
ANOVA; Figure 6A). Whereas tissue levels of miR-19b, -20a,
-21, and -31 significantly decreased at 6 months compared
to the earlier PDTX harvesting points (p= 0.05, p= 0.004,
p= 0.01, and p= 0.03 by ANOVA, respectively; Figure 6A). Glob-
ally, tissue miRNAs expression levels showed a general down-
regulation in PDTXs compared to baseline T 0 and NTC24
samples.
Serological analysis of the aforementioned miRNAs docu-
mented that circulating miR-21 and miR-210 levels were dif-
ferentially modulated according to PDTXs proliferative activ-
ity (p= 0.03, p= 0.02 by ANOVA, respectively; Figure 6B).
Conversely, serological levels of miR-19b, miR-20a, and miR-31
significantly decreased at the latter PDTX harvesting point
compared to the 1.5 and 3 months schedule (p= 0.02, p= 0.007,
and p= 0.003 by ANOVA, respectively; Figure 6B), mimicking
what observed for these small regulatory RNAs in PDTXs tissues
(Figure 6A).
In particular, PDTXs with a Ki67 immunoreactivity >50%
showed significantly higher expression of circulating miR-19b and
miR-21 levels (p= 0.04 and p= 0.03 by Mann–Whitney U test,
respectively; Figure 6C).
No other correlations could be evidenced between miRNAs and
PDTX features.
DISCUSSION
The improvement of in vivo models that closely mimic primary
NSCLC and that recapitulate tumor heterogeneity at molecular
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FIGURE 4 | Evaluation of NSCLC tissues proliferative activity. Ki67
immunohistochemical levels were analyzed in PDTXs and in their
corresponding human cancer tissues. (A) Ki67 immunoreactivity is
shown for SCC- and AC-PDTXs compared to their relative controls and
at the indicated time points. (B,C) Representative images of Ki67
staining for SCC- (B) or AC5-NSCLC cases (C) and matched PDTXs.
Original magnification 200×. (D) Analysis of Ki67 levels in SCC- or
AC-NSCLCs at baseline and after 24 h of ex vivo culture. (E)The
association of high proliferative activity (Ki67 >50%) with PDTXs
volume variation was analyzed (high volume variation= volume
variation >1). ***p<0.0001 (Fisher exact test). For all experiments,
bars represent mean±SEM.
and morphological level is a crucial element to pursue a per-
sonalized therapeutic approach and to discover new targets for
innovative treatments. In this context, the PDTXs experimental
system represents a noteworthy opportunity. Furthermore, in vivo
models of human tumors could provide novel prognostic bio-
markers besides contributing to innovative therapeutic targets
discovery and testing.
To address these ambitious goals, technical procedures must
be optimized and standardized to ensure feasibility and repro-
ducibility of PDTX generation from small tumors, the majority
of currently resected NSCLCs. In addition, the possibility to use
samples from primary tumors in a deferred setting, and not imme-
diately after surgery, could strongly expand the usefulness of tumor
xenografts.
In this scenario, our study implemented the PDTX model by
implanting 300µm-thick, precision-cut NSCLC tissue slices under
the renal capsule of CD1 athymic mice and by ex vivo cultur-
ing procedures of tumor sections before grafting. PDTX models
are entering the research laboratories to study tumor biology (10,
15, 16) and anticancer therapy (4, 17), for different malignancies.
To date, scarce data are available regarding the establishment of
PDTX from precision-cut tissue slices (18, 19) and the majority
of previously reported NSCLC xenograft models were established
from minced tissues (10, 20–22). Our model has the potential to
provide several improvements compared to PDTX derived from
minced tumor tissues. Reduced tissue thickness might improve
the proper exchange of nutrients and drugs. Furthermore, tissue
slices obtained with vibratome sectioning reduces tissue injury
compared to mincing and allows the achievement of implantable
tissues with accurate and uniform dimensions (18). With the
precision-cut technique presented here, more tumor sections from
the same samples can be obtained, compared to the tissue minc-
ing technique. Lastly, tissue sectioning by vibratome ensures a
much greater reproducibility of the implanted xenografts in dif-
ferent animals and allows greater consistency of the tumor cell
population present in the serial sections.
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FIGURE 5 | Analysis of stem cell-related genes in PDTXs and
corresponding human tumors. Expression profiles of stem cell-related
genes were investigated in SCC or AC samples at baseline. (A) Heatmap of
NANOG, c-MYC, SOX2, and ALDH1A1 expression in NSCLC tissues at T 0 and
after 24 h of ex vivo culture. SOX2 and ALDH1A1 were significantly more
expressed in SCC cases, and in PDTXs with successful engraftment
(**p<0.001, by ANOVA). Diagnosis: S, SCC; A, AC. Engraftment: H, high; L,
low. (B) Representative SCC and AC cases stained with an antibody directed
against SOX2 at T 0 and after 24 h of ex vivo cultures (NTC24). Original
magnification 200×. (C) SOX2 immunoreactivity is shown for SCC- and
AC-PDTXs and their relative controls. For all experiments, bars represent
mean±SEM.
The possibility to culture ex vivo tumor sections for 24 h before
engrafting allows to delay graft without causing tissues damage,
loss of tumor viability, or alterations of morphological features.
Patients-derived tumor xenograft models show three principal
applications. First, they are useful to test new anticancer drugs in a
context that considers both a patient-derived tumor tissue and the
in vivo situation. Second, PDTX method is appropriate to identify
biomarkers of response to therapies and, third, it could support
the delineation of a personalized therapeutic algorithm. Indeed
PDTXs may allow the preclinical evaluation of patients’ tumor
sensitivity to specific therapies in vivo.
One limitation of the previously described techniques is the
use of minced tumor tissues or of tumor pieces. These procedures
require a larger amount of tumors than precise-cut tissue slices
and,moreover, they did not grant a controlled or homogeneous tis-
sue grafting among the different receiving mice per human tumor.
The availability of large tumors is expected to decrease due to early
prevention and the use of neo-adjuvant regimens before surgery.
Furthermore, this topic is particularly relevant in lung cancer since
advanced disease is not surgically treatable.
Our study improves the use of PDTXs models because it
allows the generation of serial xenografts starting from small
tumor masses. The establishment of PDTXs from small tumors
is useful for clinical applications where tissues availability is lim-
ited. Moreover, PDTX obtained from thin organ slices are more
homogeneous and this may facilitate their implantation compared
to minced specimens.
Lastly, the possibility to culture tumor sections for 24 h grants a
time-frame that can be exploited to modulate important signaling
pathways or to delay grafting to a more convenient moment.
The data obtained from the established 48 NSCLC-PDTXs
show that PDTX tumors reproduce the histological features and
the histotype distinctive markers of patients’ primary cancers up
to 6 months after the graft. Moreover, tissue culture does not affect
PDTX ability to preserve original tumors’ characteristics nor does
it affect engrafting rate, PDTX growth, or xenografts’ proliferative
potential.
Pertaining the implantation site of PDTXs under the renal cap-
sule, our data confirm that this is suitable to obtain vascularization
of the xenograft. As described in the literature, the renal capsule
improves tumor engraftment due to the development of rich vas-
cularity, which is a key feature for graft survival especially during
the initial phase after implantation (16). The use of thin tumor
tissue slices has improved this procedure, and the presence of
vascularization was noted initially in all SCC- and AC-PDTXs,
irrespective of the final engraftment success.
However, our data suggest that host-mediated vascularization
of the PDTX is not sufficient for graft survival and expansion. In
fact our results show that PDTX growth is more dependent on the
proliferative ability of the primary cancer. Moreover, other core
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FIGURE 6 | Analysis of NSCLC-related miRNAs in PDTXs, corresponding
human tumors, and serum. Expression levels of miRNAs involved in lung
cancer progression were analyzed in PDTXs or human tumor tissues and
serum derived from SCC patients. (A) Heatmap of SCC1, SCC4, and their
relative PDTXs tissues analyzed for miRNAs expression levels. miR-19a levels
were inversely correlated with Ki67 immunoreactivity (*p=0.03 by ANOVA).
Tissue levels of miR-19b, -20a, -21, and -31 significantly decreased at
6 months compared to the PDTXs harvested at 1.5 and 3 months (respectively
*p=0.05, **p= 0.004, *p=0.01, and *p=0.03 by ANOVA). (B) Heatmap of
SCC1- and SCC4-PDTXs serum analyzed for miRNAs expression levels.
miR-19b, miR-20a, and miR-31 were significantly higher in 1.5 months old
PDTXs (respectively *p=0.02, **p=0.007, and **p=0.003, by ANOVA), and
miR-21 and -210 levels were correlated with PDTXs proliferative activity
(respectively *p=0.03, *p=0.02 by ANOVA). (C) PDTXs with high Ki67
levels (>50%) exhibited significantly high circulating miR-19b and -21 levels
(*p=0.04 and *p=0.03 by Mann–Whitney U test, respectively). For all
experiments, bars represent mean±SEM. V. Variation, volume variation; H,
high; L, low; C, graft after 24 h culture; D, direct graft.
elements such as stem-related factors may be involved in adapta-
tion of the xenograft in the host microenvironment, determining
a successful engraftment.
We also show that the tumor histotype is importantly involved
in PDTX survival and expansion. As previously reported in litera-
ture in different settings (23, 24), our model highlighted that SCC
samples show a higher engraftment ability than AC specimens.
Indeed, SCC samples that showed elevated Ki67 levels generated
SCC-PDTXs that retained a high proliferative index and increased
tumor volume.
Albeit limited by the small number of primary tumors used in
this study, no correlation was observed between the engraftment
rate and other clinical features, such as lymph node status, tumor
grade, and size. These data indicate that tumor ability to engraft
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and survive is more often associated with elevated proliferative
potential rather than aggressive features such as presence of nodal
metastases. Future studies with larger clinical series are needed to
confirm these conclusions.
However, to date, the main determinants affecting PDTX suc-
cess rate are still unknown. In order to understand other factors
involved in tumor engraftment, we analyzed the expression lev-
els of four stem cell-related genes at baseline levels in this set of
human NSCLCs. SOX2 and ALDH1A1 expression were more ele-
vated in SCC specimens than in AC tissues. In particular, SOX2
levels were retained by SCC-PDTXs and lost by AC-PDTXs com-
pared to their controls. SOX2 is a stem cell transcription factor
that plays a crucial role in the regulation of embryonic devel-
opment and it is one of the genes involved in reprograming
human somatic cells to pluripotent stem cells (25). Overexpres-
sion of SOX2 has been described in lung cancer, in particular
in SCC, where it is frequently amplified and promotes cancer
progression (26). Our data show that this stem-factor is over-
expressed at either the gene or protein level in SCC-PDTXs,
therefore suggesting that SOX2 favors tumor cell survival and
adaptation to different microenvironments, eventually sustaining
tumor growth.
Lastly, in order to investigate the suitability of our model for
novel molecular biomarkers discovery, we analyzed tissue and
serum miRNAs expression in PDTXs and corresponding human
SCC tissue. As a proof of concept, we analyzed miRNAs involved
in lung cancer.
Human miRNAs were preserved in murine hosts and could
be detected in serum and tissue of our PDTXs model. In partic-
ular, circulating miR-19b, -21, and miR-210 levels were directly
correlated with PDTXs proliferation. As a member of the miR-
17-92 cluster, miR-19b is an oncogenic key factor present in
different types of cancer (27, 28). Recently, miR-19b has been
shown to induce tumor growth and metastasis in vivo (29).
Moreover, circulating miR-19b levels have been associated with
a worse disease progression in patients affected by NSCLC (30).
miR-21 acts as an oncogenic miRNA and is involved in the reg-
ulation of cell cycle, apoptosis, invasion, and metastasis. Recent
studies demonstrated that miR-21 promoted cell proliferation
(31, 32) and its inhibition induced a cell cycle arrest at G2/M
phase (31). MiR-210 is a hypoxia-inducible miRNA in lung can-
cer and melanoma (33) and it has been detected in exosome
in vitro and in vivo (34). Moreover, serological miR-210 levels
were significantly upregulated in NSCLC patients compared to
healthy controls and were correlated with an advanced disease
(35). In line with the literature, we found increased circulat-
ing miR-210 levels in PDTX characterized by elevated tumor
proliferation.
These results suggest that our model could be a useful tool
for biomarker discovery, allowing time-course investigations over
several months of tumor engraftment and growth.
Overall, our study indicates that PDTXs established from
precise-thick tissue slices represent a valid tool to investigate cancer
biology and to discover novel biomarkers. Our results highlight the
importance of PDTX models to achieve a personalized therapeu-
tic approach with in vivo analysis and the monitoring of tumors
response to anticancer agents.
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